Broggi G, Barresi V (2023) Assessment of CDKN2A/B homozygous deletion in gliomas: to FISH or not to FISH? J Neuropathol Exp Neurol 82:742–744. https://doi.org/10.1093/jnen/nlad045

Article  PubMed  Google Scholar 

Ikeda H, Yamaguchi S, Ishi Y, Wakabayashi K, Shimizu A, Kanno-Okada H, Endo T, Ota M, Okamoto M, Motegi H, Iwasaki N, Fujimura M (2023) Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: a case report. Neuropathology 43:413–420. https://doi.org/10.1111/neup.12902

Article  PubMed  Google Scholar 

Komori T (2022) The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles. Brain Tumor Pathol 39:47–50. https://doi.org/10.1007/s10014-022-00428-3

Article  PubMed  Google Scholar 

Masui K, Onizuka H, Nitta M, Muragaki Y, Kawamata T, Komori T (2023) Recurrent high-grade astrocytoma with somatic mosaicism of isocitrate dehydrogenase gene mutation. Pathol Int 73:144–146. https://doi.org/10.1111/pin.13308

Article  CAS  PubMed  Google Scholar 

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF (2023) Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. https://doi.org/10.1056/NEJMoa2304194

Article  PubMed  Google Scholar 

Nicholson JG, Fine HA (2021) Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov 11:575–590. https://doi.org/10.1158/2159-8290.CD-20-1474

Article  CAS  PubMed  Google Scholar 

Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Narita Y, Ichimura K, Yoshida A (2021) Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol 34:688–700. https://doi.org/10.1038/s41379-020-00701-w

Article  CAS  PubMed  Google Scholar 

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A (2018) Novel, improved grading system (s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153–166. https://doi.org/10.1007/s00401-018-1849-4

Article  CAS  PubMed  Google Scholar 

Umehara T, Arita H, Yoshioka E, Shofuda T, Kanematsu D, Kinoshita M, Kodama Y, Mano M, Kagawa N, Fujimoto Y, Okita Y, Nonaka M, Nakajo K, Uda T, Tsuyuguchi N, Fukai J, Fujita K, Sakamoto D, Mori K, Kishima H, Kanemura Y (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 7:99. https://doi.org/10.1186/s40478-019-0749-8

Article  CAS  PubMed  Google Scholar 

Xi S, Huang Q, Zeng J (2024) A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma. J Neuropathol Exp Neurol 83:125–130. https://doi.org/10.1093/jnen/nlad112

Article  PubMed  Google Scholar 

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA (2018) Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. Lab Invest 98:403–413. https://doi.org/10.1038/s41374-017-0007-2

Article  PubMed  Google Scholar